Fibrocell Science Inc - 48 Year Dividend History | FCSC

Historical dividend payout and yield for Fibrocell Science Inc (FCSC) since 1971. The current TTM dividend payout for Fibrocell Science Inc (FCSC) as of June 21, 2019 is $0.00. The current dividend yield for Fibrocell Science Inc as of June 21, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.019B $0.000B
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $114.125B 12.90
Gilead Sciences (GILD) United States $88.452B 10.74
Bio-Techne Corp (TECH) United States $7.965B 54.34